Immune checkpoint receptors in autoimmunity
- PMID: 36709596
- PMCID: PMC10019320
- DOI: 10.1016/j.coi.2023.102283
Immune checkpoint receptors in autoimmunity
Abstract
Immune checkpoint receptors such as programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3), and T cell immunoglobulin and ITIM domain (TIGIT) have distinct and overlapping inhibitory functions that regulate Tcell activation, differentiation, and function. These inhibitory receptors also mediate tolerance, and dysregulation of these receptors can result in a breach of tolerance and the development of autoimmune syndromes. Similarly, antibody blockade of immune checkpoint receptors or their ligands for cancer immunotherapy may trigger a spectrum of organ inflammation that resembles autoimmunity, termed immune-related adverse events (irAE). In this review, we discuss recent advances in the regulation of autoimmunity by immune checkpoint receptors. We highlight coordinated gene expression programs linking checkpoint receptors, heterogeneity within autoreactive T-cell populations, parallels between irAE and autoimmunity, and bidirectional functional interactions between immune checkpoint receptors and their ligands.
Keywords: Autoimmunity; Checkpoint receptor ligand; Checkpoint receptors; Immune related adverse event (irAE); PD-1; PD-L1; T cell tolerance.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Similar articles
-
A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.Front Immunol. 2019 Mar 18;10:491. doi: 10.3389/fimmu.2019.00491. eCollection 2019. Front Immunol. 2019. PMID: 30936880 Free PMC article. Review.
-
Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.J Clin Endocrinol Metab. 2021 Jan 1;106(1):120-132. doi: 10.1210/clinem/dgaa701. J Clin Endocrinol Metab. 2021. PMID: 33000173
-
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.Immunol Rev. 2017 Mar;276(1):112-120. doi: 10.1111/imr.12518. Immunol Rev. 2017. PMID: 28258695 Review.
-
TIGIT: An emerging immune checkpoint target for immunotherapy in autoimmune disease and cancer.Int Immunopharmacol. 2023 Jul;120:110358. doi: 10.1016/j.intimp.2023.110358. Epub 2023 May 31. Int Immunopharmacol. 2023. PMID: 37262959 Review.
-
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.Front Immunol. 2024 Feb 5;15:1340373. doi: 10.3389/fimmu.2024.1340373. eCollection 2024. Front Immunol. 2024. PMID: 38375475 Free PMC article. Review.
Cited by
-
Serum cytokines and creatinine/cystatin C ratio as prognostic biomarkers in advanced cancer patients treated with anti-PD-1/PD-L1 therapy.Support Care Cancer. 2024 May 22;32(6):370. doi: 10.1007/s00520-024-08525-z. Support Care Cancer. 2024. PMID: 38776028 Free PMC article.
-
ZAP70 interaction with 13 mRNAs as a potential immunotherapeutic target for endometrial cancer.Oncol Lett. 2023 Apr 6;25(5):213. doi: 10.3892/ol.2023.13799. eCollection 2023 May. Oncol Lett. 2023. PMID: 37123018 Free PMC article.
-
Recent advances in biomimetic nanodelivery systems for cancer Immunotherapy.Mater Today Bio. 2025 Apr 5;32:101726. doi: 10.1016/j.mtbio.2025.101726. eCollection 2025 Jun. Mater Today Bio. 2025. PMID: 40270890 Free PMC article. Review.
-
VSTM1/SIRL-1: An Inhibitory Pattern Recognition Receptor Regulating Myeloid Cells.Eur J Immunol. 2025 Feb;55(2):e202451465. doi: 10.1002/eji.202451465. Eur J Immunol. 2025. PMID: 39989259 Free PMC article. Review.
-
Multifaceted functions of tissue-resident memory T cells in tumorigenesis and cancer immunotherapy.Cancer Immunol Immunother. 2025 Apr 26;74(6):184. doi: 10.1007/s00262-025-04035-x. Cancer Immunol Immunother. 2025. PMID: 40285796 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials